TCON Margin dodolan resik TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. - logo grafis emiten TCON

TRACON Pharmaceuticals develops targeted antibodies to combat tumors by blocking the nutrient supply to cancer cells. The GURU.Markets system highlights this level of commercial profitability, where 0.00 characterizes this valuation parameter. Growth is supported by cloud-based automation of biodata processing and a strategy to secure partners among pharma behemoths to fill the shortage of effective oncology therapies.

TRACON Pharmaceuticals, Inc (TCON) - Rentabilitas dodolan miturut bathi resik saka 04.07.2022 nganti 04.08.2024

TCON (TRACON Pharmaceuticals): rincian analitis lan laporan miturut indikator

- nilai pasar lan prakiraan target analis:
Pambiji fundamental perusahaan:TRACON Pharmaceuticals Inc. - TCON
Produk dadi TRACON Pharmaceuticals, Inc

Net profit margin measures the ultimate efficiency of a business by determining the portion of profit in every dollar earned. This metric is calculated as the ratio of net income to revenue, demonstrating sensitivity to operating expenses. By analyzing the integral net margin indicator, an investor can observe capitalization dynamics and the risks of overpayment. For TRACON Pharmaceuticals (TCON), the absence of cyclical demand for oncology drugs stabilizes this indicator, although dependence on liquidity may cause sharp fluctuations in margins.

Pesaing TRACON Pharmaceuticals (TCON)

TEM: Margin dodolan resik|Tingkat bathi miturut bathi resik Qiagen QGEN|IONS (Isis Pharmaceuticals) - Margin dodolan resik|Repligen Inc. - Margin bathi resik|Margin dodolan resik RNA|CRSP - Margin resik|GeneDx - Rentabilitas dodolan miturut bathi resik|Tingkat bathi resik RARE|Beam Tx - Margin dodolan resik|SRPT - Margin dodolan resik|TWST (Twist Bio) - Rentabilitas dodolan miturut bathi resik|Rentabilitas dodolan resik TXG|Rentabilitas dodolan miturut bathi resik NTLA|Stoke Therapeutics Inc (STOK) - Margin dodolan perusahaan|Margin dodolan resik BLFS|Margin resik WVE (Wave Life Sciences Corp)|Margin resik Maze Therapeutics MAZE|Tingkat bathi resik SION|PRME - Margin resik|Margin dodolan perusahaan Taysha TSHA|QURE: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MeiraGTx PLC|RGNX (REGENXBIO Inc) - Margin dodolan resik|solidbio.com (SLDB) - Margin dodolan perusahaan|Margin resik Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Rentabilitas dodolan resik|Benitec Biopharma - Rentabilitas dodolan miturut bathi resik|DSGN: Rentabilitas dodolan resik|RCKT: Rentabilitas dodolan miturut bathi resik|FDMT - Margin dodolan resik|LXEO: Margin dodolan resik|Korro Bio Inc. - Tingkat bathi resik|EDIT (editasmedicine.com) - Margin dodolan resik|Margin resik SLN|Margin resik ProQR Therapeutics NV (PRQR)|Codexis - Rentabilitas dodolan resik|Margin resik Sangamo SGMO|NAUT: Rentabilitas dodolan resik|MGX: Rentabilitas dodolan miturut bathi resik|Margin resik Precision BioSciences|GBIO (generationbio.com) - Rentabilitas dodolan miturut bathi resik|Margin resik boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Margin dodolan resik|Rentabilitas dodolan resik IMNN (Imunon, Inc.)|Margin dodolan resik PHIO|MBIO - Margin resik|Margin dodolan resik RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Margin resik|Applied DNA - Margin dodolan resik|Margin resik Bluebird Bio|ImmunoPrecise (IPA) - Margin resik|Margin bathi resik OMGA (Omega)|Margin resik Singular Genomics Systems|Margin resik regulusrx.com RGLS|Margin resik Syros Pharmaceuticals Inc. (SYRS)|Margin dodolan perusahaan Codex DNA|Margin resik Unity Bio UBX